PSYENCE BIOMEDICAL LTD (PBM) Stock News

Psyence Biomed Announces Closing of $2.0 Million Private Placement

NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed...

12 Health Care Stocks Moving In Monday's Pre-Market Session

Psyence Biomed Announces $2.0 Million Private Placement

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered...

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet...

12 Health Care Stocks Moving In Friday's Pre-Market Session

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO),...

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Biomed obtains exclusive worldwide supply rights to Optimi’s GMP-certified, nature-derived psilocybin for its drug development and...

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (

“Power Nickel (TSX.V: PNPN) (OTCQB: PNPNF) Announces Dividend – MIGI, PRFX, PBM, CSDX Stocks Trending Now!”

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Independent valuation of PsyLabs values Psyence Biomed’s stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and...

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the favorable...

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date...

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results...

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence...

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being ...

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin...

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin...

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder,...

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being...

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being...

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into...